These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24433001)

  • 21. Juvenile Paget's disease with compound heterozygous mutations in TNFRSF11B presenting with recurrent clavicular fractures and a mild skeletal phenotype.
    Naot D; Wilson LC; Allgrove J; Adviento E; Piec I; Musson DS; Cundy T; Calder AD
    Bone; 2020 Jan; 130():115098. PubMed ID: 31655221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin.
    Daroszewska A; Hocking LJ; McGuigan FE; Langdahl B; Stone MD; Cundy T; Nicholson GC; Fraser WD; Ralston SH
    J Bone Miner Res; 2004 Sep; 19(9):1506-11. PubMed ID: 15312251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Paget's disease of bone: new therapeutic strategies].
    D'Amore M; Lisi S; Sisto M; De Marino AV
    Recenti Prog Med; 2013 Mar; 104(3):89-92. PubMed ID: 23548950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Auricular ossification: A newly recognized feature of osteoprotegerin-deficiency juvenile Paget disease.
    Gottesman GS; Madson KL; McAlister WH; Nenninger A; Wenkert D; Mumm S; Whyte MP
    Am J Med Genet A; 2016 Apr; 170A(4):978-85. PubMed ID: 26762549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant osteoprotegerin for juvenile Paget's disease.
    Cundy T; Davidson J; Rutland MD; Stewart C; DePaoli AM
    N Engl J Med; 2005 Sep; 353(9):918-23. PubMed ID: 16135836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
    Polyzos SA; Anastasilakis AD; Litsas I; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
    J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Paget's disease of bone.
    Beyens G; Daroszewska A; de Freitas F; Fransen E; Vanhoenacker F; Verbruggen L; Zmierczak HG; Westhovens R; Van Offel J; Ralston SH; Devogelaer JP; Van Hul W
    J Bone Miner Res; 2007 Jul; 22(7):1062-71. PubMed ID: 17388729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms of CSF1 and TM7SF4 genes in a case of mild juvenile Paget's disease found using next-generation sequencing.
    Donáth J; Speer G; Kósa JP; Árvai K; Balla B; Juhász P; Lakatos P; Poór G
    Croat Med J; 2015 Apr; 56(2):145-51. PubMed ID: 25891874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK.
    Whyte MP; Tau C; McAlister WH; Zhang X; Novack DV; Preliasco V; Santini-Araujo E; Mumm S
    Bone; 2014 Nov; 68():153-61. PubMed ID: 25063546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function.
    Kostine M; Mehsen-Cetre N; Bannwarth B
    Therapie; 2017 Jun; 72(3):383-385. PubMed ID: 27745697
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension.
    Brown JP; Reid IR; Wagman RB; Kendler D; Miller PD; Jensen JE; Bolognese MA; Daizadeh N; Valter I; Zerbini CA; Dempster DW
    J Bone Miner Res; 2014 Sep; 29(9):2051-6. PubMed ID: 24692050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
    Polyzos SA; Anastasilakis AD; Makras P; Terpos E
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of Functional Osteoprotegerin: More Than a Skeletal Problem.
    Grasemann C; Unger N; Hövel M; Arweiler-Harbeck D; Herrmann R; Schündeln MM; Müller O; Schweiger B; Lausch E; Meissner T; Kiewert C; Hauffa BP; Shaw NJ
    J Clin Endocrinol Metab; 2017 Jan; 102(1):210-219. PubMed ID: 27809640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.